While further studies are needed to better understand the mechanisms of action of Nsp1 and the normal role of Nsp1 in handling stalled ribosomes in the context of viral replication and viral-host interaction, our current data suggest that Nsp1 offers a potential therapeutic agent derived from SARS-Cov-2 that can be leveraged for treating many types of human cancers driven by cMyc. This evidence concerns the gene SH2D3A and cancer.